These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 31019484)

  • 1. White Matter Changes in Cervical Dystonia Relate to Clinical Effectiveness of Botulinum Toxin Treatment.
    Blood AJ; Kuster JK; Waugh JL; Levenstein JM; Multhaupt-Buell TJ; Sudarsky LR; Breiter HC; Sharma N
    Front Neurol; 2019; 10():265. PubMed ID: 31019484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. White matter abnormalities in dystonia normalize after botulinum toxin treatment.
    Blood AJ; Tuch DS; Makris N; Makhlouf ML; Sudarsky LR; Sharma N
    Neuroreport; 2006 Aug; 17(12):1251-5. PubMed ID: 16951564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Botulinum toxin type B in the management of dystonia non-responsive to botulinum toxin type A].
    Cardoso F
    Arq Neuropsiquiatr; 2003 Sep; 61(3A):607-10. PubMed ID: 14513166
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic cortical gray matter volume changes after botulinum toxin in cervical dystonia.
    Delnooz CC; Pasman JW; van de Warrenburg BP
    Neurobiol Dis; 2015 Jan; 73():327-33. PubMed ID: 25447226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated focal dystonia phenotypes are associated with distinct patterns of altered microstructure.
    Berman BD; Honce JM; Shelton E; Sillau SH; Nagae LM
    Neuroimage Clin; 2018; 19():805-812. PubMed ID: 30013924
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Botulinum toxin type B for cervical dystonia.
    Costa J; Espírito-Santo C; Borges A; Ferreira JJ; Coelho M; Moore P; Sampaio C
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004315. PubMed ID: 15674941
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structural white matter abnormalities in patients with idiopathic dystonia.
    Bonilha L; de Vries PM; Vincent DJ; Rorden C; Morgan PS; Hurd MW; Besenski N; Bergmann KJ; Hinson VK
    Mov Disord; 2007 Jun; 22(8):1110-6. PubMed ID: 17230463
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atypical white-matter microstructure in congenitally deaf adults: A region of interest and tractography study using diffusion-tensor imaging.
    Karns CM; Stevens C; Dow MW; Schorr EM; Neville HJ
    Hear Res; 2017 Jan; 343():72-82. PubMed ID: 27473505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Duration of effect of botulinum toxin type A in adult patients with cervical dystonia: a retrospective chart review.
    Brashear A; Watts MW; Marchetti A; Magar R; Lau H; Wang L
    Clin Ther; 2000 Dec; 22(12):1516-24. PubMed ID: 11192142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced Hemispheric Asymmetry of White Matter Microstructure in Autism Spectrum Disorder.
    Carper RA; Treiber JM; DeJesus SY; Müller RA
    J Am Acad Child Adolesc Psychiatry; 2016 Dec; 55(12):1073-1080. PubMed ID: 27871642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. White matter microstructure asymmetry: effects of volume asymmetry on fractional anisotropy asymmetry.
    Takao H; Hayashi N; Ohtomo K
    Neuroscience; 2013 Feb; 231():1-12. PubMed ID: 23219841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffusion tensor imaging in patients with primary cervical dystonia and in patients with blepharospasm.
    Fabbrini G; Pantano P; Totaro P; Calistri V; Colosimo C; Carmellini M; Defazio G; Berardelli A
    Eur J Neurol; 2008 Feb; 15(2):185-9. PubMed ID: 18217887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. White matter abnormalities in obsessive-compulsive disorder: a diffusion tensor imaging study.
    Szeszko PR; Ardekani BA; Ashtari M; Malhotra AK; Robinson DG; Bilder RM; Lim KO
    Arch Gen Psychiatry; 2005 Jul; 62(7):782-90. PubMed ID: 15997020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to the treatment of limb disorders with botulinum toxin A. Experience with 187 patients.
    Pullman SL; Greene P; Fahn S; Pedersen SF
    Arch Neurol; 1996 Jul; 53(7):617-24. PubMed ID: 8929169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to botulinum toxin F in seronegative botulinum toxin A--resistant patients.
    Greene PE; Fahn S
    Mov Disord; 1996 Mar; 11(2):181-4. PubMed ID: 8684389
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and efficacy of botulinum toxin type B in the treatment of patients with cervical dystonia: summary of three controlled clinical trials.
    Lew MF; Brashear A; Factor S
    Neurology; 2000; 55(12 Suppl 5):S29-35. PubMed ID: 11188982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The botulinum toxins in the treatment of cervical dystonia.
    Brashear A
    Semin Neurol; 2001; 21(1):85-90. PubMed ID: 11346029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence-based medicine in botulinum toxin therapy for cervical dystonia.
    Ceballos-Baumann AO
    J Neurol; 2001 Apr; 248 Suppl 1():14-20. PubMed ID: 11357233
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroanatomical changes extend beyond striatal atrophy in X-linked dystonia parkinsonism.
    Brüggemann N; Heldmann M; Klein C; Domingo A; Rasche D; Tronnier V; Rosales RL; Jamora RD; Lee LV; Münte TF
    Parkinsonism Relat Disord; 2016 Oct; 31():91-97. PubMed ID: 27481033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. White matter abnormalities in gene-positive myoclonus-dystonia.
    van der Meer JN; Beukers RJ; van der Salm SM; Caan MW; Tijssen MA; Nederveen AJ
    Mov Disord; 2012 Nov; 27(13):1666-72. PubMed ID: 23114862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.